Å6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: A phase I trial

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2004 • 11,185 citations

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

2001 • 11,070 citations

Matrix Metalloproteinases: Biologic Activity and Clinical Implications

2000 • 1,533 citations

Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients

2002 • 592 citations

Comparison of Gemcitabine Versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

2003 • 382 citations

The Urokinase Plasminogen Activator System: Role in Malignancy

2004 • 381 citations

Trends in the Risks and Benefits to Patients With Cancer Participating in Phase 1 Clinical Trials

2004 • 305 citations

Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials

2003 • 221 citations

Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).

2002 • 194 citations

The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.

1998 • 186 citations

Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer

2004 • 148 citations

Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc

1999 • 130 citations

A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo

2000 • 127 citations

A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin

2000 • 87 citations

Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.

2001 • 82 citations

Should CA-125 Response Criteria Be Preferred to Response Evaluation Criteria in Solid Tumors (RECIST) for Prognostication During Second-Line Chemotherapy of Ovarian Carcinoma?

2004 • 80 citations

Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer

2002 • 70 citations

Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors

1996 • 68 citations

Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients.

1999 • 68 citations

An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer.

2002 • 66 citations

Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients

2003 • 54 citations

Phase II Study of Oxaliplatin in Platinum-Resistant and Refractory Ovarian Cancer: A Gynecologic Group Study

2003 • 45 citations

A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer

2004 • 44 citations

A Urokinase-Derived Peptide (Å6) Increases Survival of Mice Bearing Orthotopically Grown Prostate Cancer and Reduces Lymph Node Metastasis

2003 • 42 citations

Soluble Urokinase Plasminogen Activator Receptor in Preoperatively Obtained Plasma from Patients with Gynecological Cancer or Benign Gynecological Diseases

2001 • 33 citations

Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients

2003 • 23 citations

Differential mRNA Expression of Urokinase-Type Plasminogen Activator, Plasminogen Activator Receptor and Plasminogen Activator Inhibitor Type-2 in Normal Human Endometria and Endometrial Carcinomas

2000 • 20 citations

A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan

2003 • 17 citations

Safety, tolerability and pharmacokinetics of subcutaneous Å6, an 8-amino acid peptide with anti-angiogenic properties, in healthy men

2004 • 14 citations

A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer

2003 • 11 citations

Combined chemo/anti-angiogenic cancer therapy against Lewis lung carcinoma (3LL) pulmonary metastases.

2002 • 7 citations